The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib achieves cytogenetic disease remission. Molecular monitoring for residual disease has prognostic significance: rising BCR-ABL levels may provide earliest indication that a patient has become resistant to treatment. The emergence of resistance to imatinib has dampened the enthusiasm for this drug. The most common cause of resistance is the selection of leukemic clones mutated in ABL kinase domain due to amino acid substitutions with prevention of appropriate binding of the drug. Amplification and over-expression of BCR-ABL, acquired cytogenetic aberrations and modulation of drug efflux or influx transporters have been reported.
INTRODUCTION
Chronic myelogenous leukemia (CML) is a clonal disorder caused by the malignant transformation of a pluripotent stem cell. It is characterized by the Philadelphia chromosome (Ph), a genetic abnormality which arises from the reciprocal translocation t(9;22) (q34;q11) [1] . This translocation fuses the genes encoding BCR and ABL, resulting in expression of the constitutively active protein tyrosine kinase, BCR-ABL. The Ph chromosome is present in more than 90% of adult CML patients, in 15-30% of adult acute lymphoblastic leukemia (ALL) and in 2% of acute myelogenous leukemia (AML) [2] . Different molecular weight isoforms are generated, based on different breakpoints and mRNA splicing. Most CML patients have a fusion protein of 210 kDa while approximately 30% of Ph+ ALL cases and few CML cases are associated to 190 kDa BCR-ABL protein [3] . CML normally progresses through three clinically recognized phases: about 90% of patients are diagnosed during the typically indolent chronic phase (CP), which is followed by an accelerated phase (AP) and a terminal blastic phase (BP). Twenty to 25% of patients progress directly from CP to BP and the time course for progression can be extremely varied. The mechanisms behind CML progression are not fully understood [2] . There are increasing evidences that Src family kinases are involved in CML progression through induction of cytokine independence and apoptotic protection [4] . The discovery of the BCR-ABL mediated pathogenesis of CML provided the rationale for the design of an inhibitory agent that targets the specific BCR-ABL kinase activity.
Imatinib mesylate is a selective inhibitor of ABL and its derivative BCR-ABL, as well as other tyrosine kinases.
*Address correspondence to this author at the Department of Human Biotechnology and Hematology, Via Benevento 6, 00161 Roma, Italy; Tel: 003906857951; Fax: 00390644241984; E-mail: breccia@bce.uniroma1.it Imatinib provides an effective and durable therapy for CML: a recent 6 year follow-up of phase III International Randomized IFN versus STI571 (IRIS) study, showed that this agent induced complete hematologic remission in the majority (98%) of newly diagnosed patients in chronic phase of the disease and complete cytogenetic remission (CCR) in about 87% of patients [5] . With the high rate of complete cytogenetic responders, the goal of therapy has become achieving molecular responses, as measured by the reduction or elimination of BCR-ABL transcript. Major molecular response (MMR) in the IRIS trial was defined as a >3 log reduction in transcript from baseline. Obtaining MMR was associated with significantly better long-term remission duration and progression free survival (PFS). At 60-month follow-up, achievement of CCR and MMR by 12 months was associated to a PFS of 97% compared to 89% for patients with CCR but with less than MMR [5] . Early molecular response predicted for better outcome: progression of disease correlated with failure to achieve a 1 log reduction in transcript level by 3 months and a 2 log reduction by 6 months [5] .
A minority of CML patients in CP and a substantial proportion of patients in advanced phases are refractory to imatinib or lose imatinib sensitivity over time and experience relapse. Defining resistance in CML is possible only after defining response. In 2006, recommendations for definitions of failure/resistance and suboptimal response to imatinib have been proposed by European LeukemiaNet [6] ; failure was defined as no complete hematologic response at 3 months, no cytogenetic response at 6 months, less than partial cytogenetic response at 12 months, less than complete cytogenetic response at 18 months, or loss of CHR, CCR or acquisition of BCR-ABL mutations at any time. Suboptimal response was defined as incomplete hematologic response at 3 months, less than partial CR at 6 months, less than complete cytogenetic response at 12 months and less than MMR at 18 months, or acquisition of cytogenetic abnormalities in Ph+ cells, mutations of BCR-ABL or loss of MMR at any time [6] .
Despite the apparent success of imatinib therapy, the IRIS study at 5 years follow-up provides an indication of imatinib failure: 31% of patients have discontinued imatinib, with an estimated resistance (lack or loss of response) of 14% [5] . The estimated annual rate of treatment failure after the start of imatinib therapy was 3.3% in the first year, 7.5% in the second year, 4.8% in the third year, 1.5% in the fourth year and 0.9% in the fifth year. The corresponding annual rates of progression to AP or BP were 1.5%, 2.8%, 1.6%, 0.9% and 0.6%, respectively.
Several mechanisms may contribute to imatinib resistance, including increased expression of BCR-ABL through gene amplification, decreased intracellular drug concentrations caused by drug efflux proteins (such as OCT1), clonal evolution, and over-expression of Src kinases involved in BCR-ABL-independent activation of alternative pathways, such as Lyn and Hck [7] . However, 40% of resistance is attributed to the emergence of clones expressing mutated forms of BCR-ABL with amino acid substitutions in the ABL-kinase domain that impair imatinib binding through either disruption of the critical contact point or by inducing a switch from the inactive to the active conformation [8] . In this review, the mechanisms of underlying resistance in CML are reviewed and the new therapeutic options for patients resistant to imatinib are described.
DEFINITION OF RESISTANCE
Treatment resistance is an emerging challenge for clinicians who care for CML patients and the definition of resistance is more complex than simple lack or loss of some predefined response: several patients who do not have any response to imatinib exist in all phases of disease. This absence of response is known as primary resistance; patients who achieve a certain level of response (hematologic, cytogenetic, molecular) and subsequently lose that response, have an acquired resistance. Primary resistance is defined as an inability to achieve a complete hematologic remission 3 months after treatment initiation or a major cytogenetic response at 6 months. The causes of primary resistance are largely unknown and likely all the mechanisms due to insufficient inhibition of BCR/ABL are involved.
Acquired resistance is defined as progression to advanced disease or loss of response with a 5-10-fold increase in BCR/ABL transcripts. Patients who achieve a certain level of response (hematological, cytogenetic or molecular) and subsequently lose that response, can be considered as having acquired resistance [7, 8] .
MECHANISMS OF RESISTANCE
The mechanisms of resistance to imatinib have been extensively studied, since the first reports described in 2000, which led to laboratory efforts to model the development of resistance. Resistant cell lines were generated by exposure to increasing doses of imatinib, using concentrations less than IC50 (LAMA84R cell line). In these cell lines, the mechanisms identified were overexpression of BCR/ABL associated to amplification and overexpression of multidrug resistance P-glycoprotein (MDR-1 or ABCB1) [7, 8] . Moreover, resistance to imatinib was considered as a multifactorial process and the development of mutations in the tyrosine kinase domain was the most common affected mechanism. These mechanisms and their potential interactions will be reviewed in detail.
a) Mutations in the Abl Kinase Domain
Mutations in the ABL kinase domain are the most frequent clinically relevant mechanisms that change imatinib sensitivity in BCR/ABL transformed cells. Mutations can affect directly the proper binding of imatinib to the target molecule as well as binding of ATP, or lead to conformational changes of the protein, affecting binding of either imatinib or ATP in an indirect way [9] .
Mutations are more common in acquired than in primary resistance and up to now more than 50 different mutants have been described, some at higher frequency than others. These mutations are not induced by imatinib, but arise through a selection process of rare pre-existing clones, which gradually outgrow due to lack of ABL kinase inhibition. This is consistent with the evidence that mutations can be found at very low levels in patients prior to clinical imatinib resistance [10] .
The first identified mutation was the T315I which was described by Gorre et al. in 2001 [11] in 11 patients treated with imatinib for CML in blast crisis who relapsed while on treatment. In this series BCR/ABL amplification was observed in only 3 patients, whereas in 9 patients there was an identical cytosine to thymidine mutation at ABL nucleotide 944 observed with sequencing analysis. This mutation was the result of a single amino-acid substitution at position 315: threonine 315 forms a crucial hydrogen bond with imatinib and the absence of an oxygen atom in the substituted isoleucine prevents bond formation. The isoleucine induces a steric clash with imatinib, which led to a designation as "gatekeeper" for imatinib.
Mutations can be categorized into 4 groups, based on their position: mutations that directly impair imatinib binding, such as the T315I above described [11] ; mutations within the p-loop mutations; mutations in the activation loop (a-loop), preventing the kinase from achieving the conformation required for imatinib binding; mutations of the catalytic domain. The domain of P-loop is a highly conserved glycine rich sequence spanning amino-acids from 248 to 256, which interacts with imatinib through hydrogen and van der Waals bonds. The mutations modify the flexibility of p-loop and destabilize the conformation required for imatinib binding. While some groups found that p-loop mutations are associated with a more rapid progression to advanced disease phase than mutations in other regions, the group of MD Anderson did not to confirm this finding.
The activation loop begins at amino acid 381 with a highly conserved motif of 3 amino acid residues (aspartate-phenylalanine-glycine): this region can adopt a closed or open conformation and imatinib forces ABL into the inactive conformation. Mutations in this region can alter the energetic balance required to stabilize the closed conformation of the loop and favour the open conformation.
The catalytic domain has a close topologic relationship with the activation loop and mutations in this region can also influence the binding of imatinib.
The frequency of mutations differs because of the phase of the disease and the tool used for the detection. Early studies used the direct sequencing with a sensitivity of 20-30%; sequencing after subcloning of PCR products improved sensitivity, but is time consuming and laborious. Alternative methods include allele specific oligonucleotide PCR, restriction-fragment-length polymorphism-based assay and peptide-nucleic-acid-based clamping technique. Denaturing high performance liquid chromatography (DHPLC) has been described in several reports and is now considered as the best tool for large screening. With this technique the sensitivity improved to 1-5% and to 5-10% for M351T. Using this latter tool, mutations have also been detected in patients in complete cytogenetic remission and in patients imatinib-naïve in advanced phase, but not in chronic phase. However, detection of mutations in such patients did not always result in progressive disease while on therapy, because low levels of mutant clones do not have a similar impact as clones detected when disease burden is high [12, 13] .
b) OVEREXPRESSION OF BCR/ABL
This mechanism of resistance was reported for the first time by Gorre et al. [11] . In a study by Mahon et al. [14] overexpression of BCR/ABL was shown to be the most frequent cause of resistance identified in cell lines developed to study resistance. A large study by Hochhaus et al. [15] on 66 patients with primary or acquired resistance described only 2 patients with genomic amplification. The phenomenon in vivo was reported in a relatively small proportion of patients, with a percentage of 18% [12] .
In contrast to some mutations that can lead to complete imatinib resistance, it has been suggested that higher concentrations of imatinib can be able to overwhelm the genomic amplification. This type of resistance can be detected by interphase fluorescence in situ hybridization using fluorescently labeled probes for BCR and ABL genes. The mechanism underlying genomic amplification is likely the genomic instability and it has been reported that overexpression of BCR/ABL might itself be harmful to the cell: in fact, cell lines with amplification were noted to have dose-dependent differences in growth-factor dependence, clonogenity and migration. It is also possible that overexpression of BCR/ABL may be an early phenomenon, preceding the emergence of a dominant clone with a mutant kinase domain [7] .
c) Drug Transporters
Several drug efflux and influx mediators are involved in the mechanisms of resistance to imatinib [7] . The principal is MDR1 gene product, Pgp protein, a well-described mechanism of resistance to chemotherapy in different cancers. This protein reduces intracellular drug concentrations and leads to ineffective levels of the drug reaching its target. Imatinib as well as other tyrosine kinase inhibitors is substrate of Pgp and the intracellular levels of the drug were shown to be significantly lower in Pgp-expressing cells. Pgp overexpression has not been reported directly in patients with resistance to imatinib, although the addition of a Pgp pump inhibitor, PSC833, to cell cultures from imatinib-resistant CML patients produced a decrease in colony formation. The role of ABCB1 as a possible mechanism of resistance to imatinib has been suggested, but its role is still unclear [16] . In a study by Galimberti et al. [17] an overexpression of ABCB1 was found in patients who did not achieve at least a major cytogenetic remission, whereas Mahon et al. [14] were unable to confirm this correlation.
Two other drug transporters, the breast cancer resistance protein (ABCG2) and human organic cation transporter 1 (OCT-1), have been described as possible mechanism to induce imatinib resistance. ABCG2 transports certain drugs such as quinoline-based camptothecins out of the cells. Different evidences on the relationship between ABCG2 and imatinib have been reported: imatinib may reverse ABCG2-mediated resistance, but has not been shown to be an ABCG2 substrate for efflux by itself [18] . On the other hand, Burger et al. [19] suggested that imatinib levels are significantly decreased in ABCG2-overexpressing cells and the role of imatinib as substrate needs further evaluation.
The drug transporter OCT1 mediates the active transport of imatinib into the cells and inhibition of OCT-1 decreases the intracellular concentration of imatinib, which may predict for a less favorable molecular response [20] . Patients with a low baseline expression of OCT-1 may not achieve a complete cytogenetic response and a study by Crossman et al. found a significant correlation between level of OCT-1 and subsequent response [21] .
d) Oral Availability and Plasma-Protein Binding
Several studies have reported on the variability of imatinib concentrations between patients treated with similar doses of drug. They depend from gastrointestinal absorption and drug metabolism in the liver. Imatinib is metabolised by cytochrome p450 isoenzyme 4A (CYP3A4), which differs between individuals and is responsible of potential drug interactions. In 2007, Picard et al. assayed plasma imatinib concentrations and established a mean of concentration at 1002 ng/ml [22] .
Mean through concentrations were higher in patients with good responses than in patients with less favourable outcomes, confirming that drug level should be measured in patients without a good response [23] .
Imatinib is bound to protein, predominantly albumin, but also to alpha1-acid glycoprotein. It was hypothesized that excessive binding of imatinib to alpha1-acid glycoprotein could interfere with its therapeutic effect [24] . Erythromycin treatment which binds to alpha1-acid glycoprotein has been shown to overcome the phenomenon of resistance in mice treated with imatinib.
e) Clonal Evolution
BCR/ABL has been associated to genomic instability which is of particular relevance during disease progression from chronic phase to accelerate or blastic phase. The acquisition of additional chromosomal abnormalities in the Phpositive cell population correlates with a decreased response to imatinib in terms of cytogenetic response, haematological response and overall survival. Lahaye et al. [25] found that failure to achieve a complete hematologic response was associated to clonal evolution in more cases as compared to development of mutations. In a series of 171 patients reported by Jabbour et al. [26] , clonal evolution was present at the time of imatinib failure in 24% of assessable cases and mutations were more likely detected in this category of patients.
f) BCR/ABL Independent Mechanisms
Lyn and Hck of the Src family kinases are activated in BCR/ABL expressing cell lines. It has been reported an overexpression of Lyn in imatinib-resistant cell lines generated by incubation of increasing concentrations of imatinib or in cells of imatinib resistant patients [27] .
It has been also reported an overexpression of signal involved in transduction and transcriptional regulation, suggesting that pathways downstream of BCR/ABL and independent of kinase activity may confer resistance to imatinib [28] .
NOVEL ABL KINASE INHIBITORS TARGETING IMATINIB RESISTANT BCR/ABL
After the discovery of resistance to imatinib, a number of potent ABL kinase inhibitors with activity proved both in vivo and in vitro against ABL kinase mutant BCR/ABL cell lines have been identified. New compounds that bind to and inhibit the ABL kinase but are less affected by point mutations through their static conformation are now in clinical trials. The analysis of crystal structure of imatinib-ABL complex has proven helpful in identifying potential critical residues that hinder interaction of imatinib with mutated ABL. We will summarize recent findings on three novel drugs that have been developed using different strategies.
a) Nilotinib
Nilotinib (AMN107), an oral novel tyrosine kinase inhibitor is 20-50-fold more potent than imatinib. It binds to the inactive conformation of BCR-ABL, stabilizing the molecule in its inactive form with the p-loop folding over the ATP binding site and activation loop, blocking the substrate binding site so that ATP-phosphate binding is prevented and catalytic activity of the enzyme is inhibited [29, 30] . Nilotinib effectively inhibits the autophosphorylation of BCR-ABL on Tyr177, which is an important binding site for the Grb2 adapter protein. The Tyr177 residue is involved in BCR-ABL pathogenesis through the regulation of diverse signaling pathways, including the activation of the PI3K and Ras/Erk pathways. The phosphorylated Tyr177 residue and its associated proteins were also identified as key lineage determinants and regulators of the severity of BCR-ABL transformation [31] .
Nilotinib is also active against PDGFR-and -, and ckit. It has demonstrated activity against all BCR-ABL mutations that are known to cause imatinib resistance (32 of 33) except T315I: in fact, Nilotinib prolonged survival of mice injected with leukemic cells expressing wild-type and imatinib-resistant mutations of BCR-ABL [32] .
Nilotinib is taken-up by cells through different mechanisms as compared to imatinib: although patient sensitivity to imatinib depends upon the expression of the organic cation transporter, OCT-1, the transport of nilotinib is independent of this protein [33] .
Overexpression of BCR-ABL is a possible mechanism for nilotinib resistance, but it is more likely that this phenomenon arises through the emergence of clones expressing nilotinib-resistant mutated forms of BCR-ABL. Using a cellbased screening assay, it was seen that the number of mutations that arose with nilotinib treatment was lower than with imatinib treatment. There was some overlap, such as the following mutations which occurred in both treatment conditions: Q252H, Y253H, E255K, F311I, T315I, S349L, and F359I [34, 35] .
In a phase I dose-escalation study, nilotinib was given to 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (17 patients in CP, 56 in AP, 24 in myeloid BP, 22 in lymphoid BP or Ph+ ALL). Daily doses ranged from 50 to 1,200 mg once daily or 400 mg and 600 mg twice daily, and were assigned in nine dose cohorts of patients, to evaluate the safety and tolerability of the drug. A complete hematological response was achieved in 92% and a cytogenetic response in 53% (35% being complete cytogenetic responses) of the 17 chronic phase patients. No differences were observed between patients with or without BCR-ABL mutations, except for 2 patients with T315I mutation who exhibited marked resistance to nilotinib [36] . Hematological serious adverse events of grade 3 or 4, in CP patients, included thrombocytopenia and neutropenia, occurring in 20% and 13%, respectively, while non-hematological events consisted of an elevation of bilirubin and serum lipase levels. Grade 3-4 unconjugated bilirubinemia was reported in 14% of patients receiving 600 mg twice daily; this increase was not accompanied by an increase in levels of amino-transferase or evidence of increased hemolysis. Nilotinib had a serum half-life of 15 hours and was initially given as a single daily dose. Saturation of serum levels was observed at doses ranging from 400 to 1,200 mg daily. With the schedule modified to a twice-daily regimen, there was an increase of 50-80% in peak serum levels and in the area under the concentration versus time curve at the same total daily dose of the drug. The dose recommended for future study was 400 mg twice daily and with this schedule there was a significant reduction in the phosphorylation of AKT, CRKL, STAT1, and STAT5 compared with baseline levels [36] . Among 56 AP patients, 72% of those with hematologic evidence of disease obtained a CHR: a total of 55% of patients obtained a cytogenetic response, which was complete in 8 patients, partial in 7 and minor in 5. Among 24 patients with myeloid BP, 42% achieved a CHR and 29% a cytogenetic response (1 patient CCR); of the 9 patients with lymphoid BP or Ph+ ALL, 33% achieved a CHR and 22% a cytogenetic response (1 patient CCR). In a Phase II trial, 318 patients were enrolled after imatinib failure or intolerance. Based on pharmacokinetic study of phase I, nilotinib was administered at 400 mg twice daily and could be escalated to 600 mg twice daily if patients had not obtained an hematologic response at 3 months, a major cytogenetic response at 12 months, or if they showed loss of hematologic or cytogenetic response or disease progression at any time. The results referred to the initial cohort of 280 patients with at least 6 months of follow-up: 194 (69%) patients were imatinib resistant and 86 (31%) patients were imatinib intolerant. Sixty-five % of analyzed patients remained on study and the main causes of discontinuation were adverse events (15%) and disease progression (11%). The rate of major cytogenetic responses ( 35% Ph + cells) was 48%, the rate of complete response was 31% and of partial response was 16%. The rate of patients who persisted in MCR was 96% (only 5 out of 134 patients discontinued therapy due to progression or death) and the estimated 1-year overall survival was 95% (a total of 10 patients died: 2 during treatment and 8 during the long term followup). Mutational study was available for 182 patients and 28 different mutations were detected: MCR was achieved in 42% of mutated patients (versus 51% of non mutated) and CCR in 23% of mutated patients (versus 35% of non mutated). MCR and CHR were observed across all BCR-ABL genotypes, with the exception of the T315I mutation, identified in 4 patients, and the E255V and E274K mutations, identified both in 1 patient. The rates of responses appeared to be affected by preclinical IC50 to nilotinib: mutations with IC50 less than 100 nM reached MCR at the rate of 43% versus a rate of 15% for mutations with IC50 ranging from 201 to 800 nM. Regarding the safety profile, the most commonly reported non-hematologic adverse events were similar to those observed in phase I trial (rash, nausea, pruritus, headache, fatigue). The most commonly reported grade 3-4 hematologic abnormalities were neutropenia (29%) and thrombocytopenia (29%). Preclinical studies indicated that nilotinib could potentially prolong the QT interval: an incidence of 1% of QTc intervals exceeding 500 milliseconds according to Fridericia correction was reported. [37] .
b) Dasatinib
Dasatinib was approved by the US Food and Drug Administration (FDA) for the treatment of CML patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy [38] . It is also indicated for the treatment of adults with Ph + ALL who have become resistant or intolerant to other treatments [39] . Dasatinib inhibits BCR-ABL with a 50% inhibitory concentration (IC50) of <1 nmol/L compared with nilotinib. It is active against c-KIT, PDGFR, and EPHA2, as well as against members of Src kinase family, such as Lyn, Yes, and Src, with an IC50 of 0.5 nmol/L [40] .
The structure of dasatinib is based on a different chemical scaffold to imatinib and has a 325-fold greater potency. It binds both the inactive and active conformations of the ABL kinase domain; although the central cores of dasatinib and imatinib share an overlapping region, they extend in opposite directions [40] .
Dasatinib is active against all the BCR-ABL mutations conferring imatinib-resistance that have been tested to date, except the T315I mutation; in fact, it is not involved in critical interactions with many of the residues that are subject to mutation, rendering this drug much more active [41] .
Dasatinib is not a substrate of multidrug resistance protein-1 (MDR1), an efflux protein expressed on normal and leukemic hematopoietic stem cells [42] . There is evidence that it may target an earlier progenitor population than imatinib, although the most primitive quiescent cells seem to be inherently resistant to both drugs [43] .
The results of phase I trial comprised 84 patients with imatinib resistance or intolerance, with disease in either chronic (n=40) or advanced phase (n=44). The maximum tolerated dose of dasatinib was found to be 70 mg taken orally, twice daily. Rate of complete hematological response in CP patients post imatinib failure was 88% and the complete cytogenetic response rate was 33%. Hematological side effects included grade 3-4 neutropenia in 50% of patients and thrombocytopenia in 60%. Non-hematological adverse events included pleural effusions in 5-10% of the entire cohort [44] . A Phase II trial was completed and led to the approval of dasatinib for CML patients resistant or intolerant to imatinib. Several programs were published: in the START C program, dasatinib was administered at 70 mg twice daily and 387 patients with resistance (75%) or intolerance (25%) were included. Complete hematological response was reached in 90% of cases; complete cytogenetic responses were seen in 30% of resistant patients and PCR in 12%, whereas in intolerant patients responses were 78% (68% CCR and 10% PCR). In this study, BCR-ABL mutations were detected in 160 of 363 patients (44%), with G250E and T315I being the most frequently found [45] . Responses in patients with BCR-ABL mutations at baseline were comparable to overall response rates, especially for p-loop mutations. The progression-free survival (PFS) rate after 10 months of treatment was 88%. The adverse events were similar to those observed in phase I (diarrhea, headache, rash, edema, and pleural effusions) and were severe in <5% of patients [45] .
The START R trial included imatinib-failing patients who were randomized in a ratio of 2:1 to receive dasatinib 70 mg twice daily or imatinib 800 mg daily. Complete hematological response was obtained in 93% versus 82% of patients treated with dasatinib and high-dose imatinib, respectively. Higher major cytogenetic response rate was observed in dasatinib arm as compared to imatinib therapy (52% vs. 33%; p=0.023), with the rate of complete cytogenetic response being 40% versus 16%, respectively (p=0.004) [42] .
Major molecular responses were also more frequently seen in dasatinib-treated patients (16% vs. 4%; p=0.038). To avoid potential bias, patients with known specific mutations before study entry were excluded; at baseline 139 patients were studied (44% of patients mutated in the dasatinib arm and 24% in imatinib arm). Pleural effusion was more common in dasatinib-treated patients (17% vs. 0%) and cytopenias were more frequent and severe in this population than in imatinib-treated patients [46] .
The subsequent Phase III trial was an international (139 centers), open-label study, CA180034, which enrolled 662 patients resistant or intolerant to prior imatinib therapy, randomized to receive either 140 mg or 100 mg of dasatinib administered in doses once (QD) or twice daily (BID). Complete hematological response was achieved in 92% of the 100 mg QD cohort patients and 89% of the 70 mg BID cohort patients. Complete cytogenetic responses were achieved in 46% and 50% of 100 mg QD and 70 mg BID patients, respectively, while major molecular responses (ratio <0.1%) were achieved in 17 and 22% of patients, irrespective of the treatment schedule. However, in the arm receiving 100 mg QD, fewer non-hematological adverse events (pleural or pericardial effusions) and lower incidence of thrombocytopenia were observed. Consequently, were recorded less drug interruptions for adverse events (58% vs. 71% in the 70 mg BID arm). The PFS rate was 91% in the 100 mg QD arm versus 84% in the 70 mg BID arm patients (p=0.032) [47] .
c) Bosutinib
Bosutinib, is a potent inhibitor of Src kinase activity and has 200 times more potent inhibitory activity against BCR-ABL than imatinib, but minimal inhibitory activity against PDGFR and c-kit [48] . It retains activity against a wide variety of BCR-ABL kinase domain mutations, except T315I [49] . Responses in 69 patients with relapsed or imatinibresistant chronic phase CML or Ph+ ALL who were treated with bosutinib, were presented at ASCO meeting in 2007. The optimal dose was established to be 500 mg per day [50] . A Phase II trial included 98 patients whose previous treatments included IFN-, imatinib, dasatinib, and nilotinib. Among the patients who failed single-agent imatinib therapy, 57 were resistant and 21 were intolerant. Of 23 resistant patients who were analysed for hematological response, 17 (74%) achieved a complete hematological response. Of 36 imatinib-resistant patients available for cytogenetic assessment, 15 (42%) achieved a major cytogenetic response, including 12 complete responses (33%). Among evaluable imatinib intolerant patients (n=7), four (57%) achieved a major cytogenetic response and three a complete response (43%). Five of the six intolerant patients (83%) who were evaluated achieved a hematological response. Among eight patients who had previously received nilotinib or dasatinib, three (38%) achieved a complete haematological response and two (25%) a major cytogenetic response. Among imatinib-resistant patients, median time to major cytogenetic response was 47.3 weeks. Of 40 imatinib-resistant patients evaluable for molecular response, 13 (33%) achieved major molecular responses, 6 (15%) of which were complete. Of 72 patients with samples tested for BCR-ABL mutations, 27 (38%) had 19 different gene mutants. A complete haematological response occurred in four of five patients with p-loop mutations and in 14 of 17 with non-p-loop mutations, with a major cytogenetic response occurring in one of four and eight of 19 patients, respectively. Generally, treatment was well tolerated. The most common side effects were gastrointestinal (nausea, vomiting and diarrhea), but they were usually grade 1-2, and grade 3-4 occurred in < 5% of patients [50] . Ten patients reported grade 1-2 edema and two patients had pleural effusions, one in conjunction with a pericardial effusion considered unrelated to treatment [50] .
CONCLUSIONS
The current first-line therapy for newly diagnosed CML is imatinib; however, imatinib resistance represents a significant clinical problem that may not be overcome by simple dose escalation. Methods of management changed in rapid development and definitive statements are not conclusive. For patients with response to imatinib, no change in therapy has been suggested. For patients who have developed primary or secondary resistance, novel inhibitors may be effective. Dasatinib has demonstrated efficacy in patients with imatinib intolerance or resistance; nilotinib has shown activity in imatinib-intolerant and resistant patients and was recently approved in the USA. Bosutinib is the most recently developed TKI that has shown efficacy in CML and is currently undergoing Phase III trials. It is very important, during treatment with TKIs, to monitor patients by sensitive RT-PCR and RQ-PCR, check for mutations and change therapy when appropriate. CML treatment can now offer the potential for durable responses in most patients and with continuing advances in research, prognosis for these patients will only improve.
